Tevosol is currently known for the development of EVOSS (Ex-Vivo Organ Support System) to preserve, assess, and reclaim donor organs for transplant. The system is the weight and size of a regular ice cooler, affordable, and maintains the organ at normal body temperatures. The company completed its first human transplants in 2019, secured key strategic partnerships and capital financing in 2020, and aims to manufacture, trial, and commercialize EVOSS Lung in 2021. Product research and development, design and engineering, assembly and packaging, and global distribution will remain wholly based in Edmonton, Alberta.
BDO’s M&A and Capital Markets team acted as exclusive financial advisor to Tevosol, assisting the company’s management and shareholders through the entire divestiture process.
"From our founding, Tevosol has benefited from a full range of BDO services—audit, tax, consulting, and now M&A advisory. Our BDO M&A and Capital Markets team provided steady guidance and trustworthy support in closing our cross-border deal across a closed border in the time of pandemic. They always kept our objectives firmly in mind and the big picture in plain view. I recommend BDO for any young company facing tough odds and looking to turn hard challenges into bright prospects."
Ron Mills, Chief Executive Officer, Tevosol